0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cytokines > IL-6 > IL6-H8218

Biotinylated Human IL-6 Protein, epitope tag free, ultra sensitivity (primary amine labeling)

  • Synonym
    IL6,Interleukin-6,BSF2,HSF,IFNB2
  • Source
    MABSol® Biotinylated Human IL-6, epitope tag free, primary amine labeling (IL6-H8218) is expressed from human HEK293 cells. It contains AA Val 30 - Met 212 (Accession # NP_000591). It is the biotinylated form of ActiveMax® Human IL-6, Tag Free (IL6-H4218).
    Predicted N-terminus: Val 30
  • Molecular Characterization
    Online(Val 30 - Met 212) NP_000591

    The product does NOT contain any epitope tags. The protein has a calculated MW of 20.8 kDa. The protein migrates as 24-27 kDa on a SDS-PAGE gel under reducing (R) condition due to different glycosylation.

  • Biotinylation
    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.
  • Biotin:Protein Ratio
    The biotin to protein ratio is 4-5.5 as determined by the HABA assay.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) SDS-PAGE gel

Biotinylated Human IL-6, epitope tag free, primary amine labeling on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Biotinylated Human IL-6, epitope tag free, primary amine labelingBiotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) ELISA bioactivity

Immobilized Human IL-6 R alpha, Fc Tag (Cat. No. ILR-H5259) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) with a linear range of 1-20 ng/mL (QC tested).

Bioactivity-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) on SA Biosensor, can bind Human IL-6 R alpha, His Tag (Cat. No. ILR-H4223) with an affinity constant of 45.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Bioactivity-Cell based assay
Human FcRn Heterodimer Protein Cell_Base

Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL (Routinely tested).

  • Background
    Interleukin 6 (IL-6) is also known as HGF, BSF2,HSF, IFNB2 and IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine that regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions.It is secreted by T cells, macrophages , monocytes, fibroblasts,endothelial cells,et.al. to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. Interleukin 6 has been shown to interact with interleukin-6 receptor and glycoprotein. IL-6 is relevant to many disease processes such as diabetes,atherosclerosis, depression,Alzheimer's Disease,systemic,lupus erythematosus,prostate cancer and rheumatoid arthritis. Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.Hence there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.
  • Clinical and Translational Updates
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $290.00

Price(USD) : $1250.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:5 Details
  • Number of Drugs in Clinical Trials:18 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop